Author(s)

Mieko Yanagisawa, Keigo Yorozu, Mitsue Kurasawa, Yoichiro Moriya, Naoki Harada

Product Research Department, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan.

We examined the antitumor efficacy of the capecitabine (CAPE) plus cyclophosphamide (CPA) combination as a 2^nd-line therapy after paclitaxel (PTX) plus bevacizumab (BEV) treatment in a xenograft model of human triple negative breast cancer (TNBC) cell line, MX-1. After tumor growth was confirmed, PTX (20 mg/kg; i.v.) + BEV (5 mg/kg; i.p.) treatment was started (Day 1). Each agent was administered once a week for 5 weeks and tumor regression was observed for at least the first 3 weeks. For 2^nd-line treatment, we selected mice in which the tumor volume had increased from day 29 to day 36 and was within 130 - 250 mm³ on day 36. After randomization of mice selected on day 36, CPA (10 mg/kg; p.o.) and CAPE (539 mg/kg; p.o.) were administered daily for 14 days (days 36 - 49), followed by cessation of the drugs for 1 week. The tumor growth on day 57 was significantly suppressed in the CPA, CAPE and CAPE + CPA groups as compared with the control group (p < 0.05). Furthermore, the antitumor activity on day 57 of CAPE + CPA was significantly stronger than that of CPA or CAPE alone (p < 0.05). The thymidine phosphorylase (TP) level in tumor tissue was evaluated by immunohistochemistry on day 50, and was significantly higher in the CPA group than those in the control group (p < 0.05). Upregulation of TP in tumor tissues by CPA treatment would increase the 5-FU level in tumor tissues treated with CAPE. This would explain the possible mechanism that made CAPE + CPA superior to CAPE alone in the 2^nd-line treatment. Our preclinical results suggest that the CAPE + CPA combination therapy may be effective as 2^nd-line therapy after disease progression in PTX + BEV 1^st-line treatment for TNBC patients.

Triple Negative Breast Cancer; Capecitabine; Cyclophosphamide; Bevacizumab; Paclitaxel; Xenograft Model

M. Yanagisawa, K. Yorozu, M. Kurasawa, Y. Moriya and N. Harada, "Combination Therapy of Capecitabine with Cyclophosphamide as a Second-Line Treatment after Failure of Paclitaxel plus Bevacizumab Treatment in a Human Triple Negative Breast Cancer Xenograft Model," Journal of Cancer Therapy, Vol. 4 No. 7, 2013, pp. 1236-1241. doi: 10.4236/jct.2013.47144.